Summary for Mizoribine

  • Trade Name: Bredinin (Asahi Kasei Pharma)
  • Indications: Rheumatoid arthritis, systemic lupus erythematosus, prevention of rejection in renal transplantation, lupus nephritis, nephrotic syndrome
  • Class: Immunosuppressant
  • Half-life: 6 hours
  • Clinically important, potentially hazardous interactions with:
    None known

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top